Predictive and prognostic value of inflammatory markers in locally advanced rectal cancer (PILLAR) - A multicentric analysis by the Italian Association of Radiotherapy and Clinical Oncology (AIRO) Gastrointestinal Study Group.
Inflammatory markers
Neoadjuvant radiotherapy
Predictive factors
Prognostic factors
Rectal cancer
Journal
Clinical and translational radiation oncology
ISSN: 2405-6308
Titre abrégé: Clin Transl Radiat Oncol
Pays: Ireland
ID NLM: 101713416
Informations de publication
Date de publication:
Mar 2023
Mar 2023
Historique:
received:
30
11
2022
revised:
08
01
2023
accepted:
09
01
2023
entrez:
20
3
2023
pubmed:
21
3
2023
medline:
21
3
2023
Statut:
epublish
Résumé
Patients (pts) affected with locally advanced rectal cancer (LARC) may respond differently to neoadjuvant chemoradiotherapy (nCRT). The identification of reliable biomarkers able to predict oncological outcomes could help in the development of risk-adapted treatment strategies. It has been suggested that inflammation parameters may have a role in predicting tumor response to nCRT and survival outcomes and in rectal cancer, but no definitive conclusion can be drawn at present. The aim of the current study is to evaluate the role of baseline inflammatory markers as prognostic and predictive factors in a large multicentric Italian cohort of LARC pts. Patients diagnosed with LARC from January 2002 to December 2019 in 9 Italian centers were retrospectively collected. Patients underwent long-course RT with chemotherapy based on fluoropyrimidine ± oxaliplatin followed by surgery. Inflammatory markers were retrieved based on a pre-treatment blood sample including HEI (hemo-eosinophils inflammation index), SII (systemic index of inflammation), NLR (neutrophil-to-lymphocyte ratio), PLR (platelet-to-lymphocyte ratio) and MLR (monocyte-to-lymphocyte ratio). Outcomes of interest were pathological complete response (pCR), disease-free survival (DFS), and overall survival (OS). 808 pts were analyzed. pCR rate was 22 %, 5yOS and 5yDFS were 84.0% and 63.1% respectively. Multivariate analysis identified that a NLR cut-off value >1.2 and SII cut-off value >500 could predict pCR (p = 0.05 and 0.009 respectively). In addition to age, extramesorectal nodes and RT dose, MLR >0.18 (p = 0.03) and HEI = 3 (p = 0.05) were independent prognostic factors for DFS. Finally, age, RT dose, MLR with a cut-off >0.35 (p = 0.028) and HEI = 3 (p = 0.045) were independent predictors of OS. Higher values of baseline composite inflammatory markers can serve as predictors of lower pCR rates and worse survival outcomes in LARC patients undergoing nCRT. More reliable data from prospective studies could lead to the integration of these inexpensive and easy-to-derive tools into clinical practice.
Sections du résumé
Background
UNASSIGNED
Patients (pts) affected with locally advanced rectal cancer (LARC) may respond differently to neoadjuvant chemoradiotherapy (nCRT). The identification of reliable biomarkers able to predict oncological outcomes could help in the development of risk-adapted treatment strategies. It has been suggested that inflammation parameters may have a role in predicting tumor response to nCRT and survival outcomes and in rectal cancer, but no definitive conclusion can be drawn at present. The aim of the current study is to evaluate the role of baseline inflammatory markers as prognostic and predictive factors in a large multicentric Italian cohort of LARC pts.
Methods
UNASSIGNED
Patients diagnosed with LARC from January 2002 to December 2019 in 9 Italian centers were retrospectively collected. Patients underwent long-course RT with chemotherapy based on fluoropyrimidine ± oxaliplatin followed by surgery. Inflammatory markers were retrieved based on a pre-treatment blood sample including HEI (hemo-eosinophils inflammation index), SII (systemic index of inflammation), NLR (neutrophil-to-lymphocyte ratio), PLR (platelet-to-lymphocyte ratio) and MLR (monocyte-to-lymphocyte ratio). Outcomes of interest were pathological complete response (pCR), disease-free survival (DFS), and overall survival (OS).
Results
UNASSIGNED
808 pts were analyzed. pCR rate was 22 %, 5yOS and 5yDFS were 84.0% and 63.1% respectively. Multivariate analysis identified that a NLR cut-off value >1.2 and SII cut-off value >500 could predict pCR (p = 0.05 and 0.009 respectively). In addition to age, extramesorectal nodes and RT dose, MLR >0.18 (p = 0.03) and HEI = 3 (p = 0.05) were independent prognostic factors for DFS. Finally, age, RT dose, MLR with a cut-off >0.35 (p = 0.028) and HEI = 3 (p = 0.045) were independent predictors of OS.
Conclusions
UNASSIGNED
Higher values of baseline composite inflammatory markers can serve as predictors of lower pCR rates and worse survival outcomes in LARC patients undergoing nCRT. More reliable data from prospective studies could lead to the integration of these inexpensive and easy-to-derive tools into clinical practice.
Identifiants
pubmed: 36935859
doi: 10.1016/j.ctro.2023.100579
pii: S2405-6308(23)00004-6
pmc: PMC10014327
doi:
Types de publication
Journal Article
Langues
eng
Pagination
100579Informations de copyright
© 2023 The Authors. Published by Elsevier B.V. on behalf of European Society for Radiotherapy and Oncology.
Déclaration de conflit d'intérêts
The authors declare that they have no known competing financial interests or personal relationships that could have appeared to influence the work reported in this paper.
Références
N Engl J Med. 2004 Oct 21;351(17):1731-40
pubmed: 15496622
BMC Cancer. 2019 Jul 5;19(1):664
pubmed: 31277604
Radiother Oncol. 2021 Jan;154:154-160
pubmed: 32966845
Sci Rep. 2020 May 15;10(1):8017
pubmed: 32415197
World J Surg. 2019 Jan;43(1):260-272
pubmed: 30151676
Int J Radiat Oncol Biol Phys. 2018 Nov 15;102(4):765-774
pubmed: 29891200
Lancet Oncol. 2021 Jan;22(1):29-42
pubmed: 33301740
Immunity. 2019 Jul 16;51(1):27-41
pubmed: 31315034
Radiat Oncol. 2021 Jul 13;16(1):129
pubmed: 34256782
J Immunother Cancer. 2019 Mar 28;7(1):85
pubmed: 30922400
Cancer Cell. 2018 Jun 11;33(6):965-983
pubmed: 29657130
Radiat Oncol. 2014 Dec 18;9:295
pubmed: 25518933
Dig Surg. 2015;32(6):496-503
pubmed: 26544755
Oncotarget. 2018 Apr 27;9(32):22368-22382
pubmed: 29854285
Cancers (Basel). 2021 Feb 07;13(4):
pubmed: 33562397
Int J Mol Sci. 2019 May 17;20(10):
pubmed: 31108935
Lancet. 2009 Mar 7;373(9666):811-20
pubmed: 19269519
Med Sci Monit. 2017 Oct 08;23:4826-4833
pubmed: 28988257
Clin Transl Radiat Oncol. 2017 May 17;4:8-14
pubmed: 29594202
J Coll Physicians Surg Pak. 2021 Apr;30(4):399-404
pubmed: 33866724
Mol Cancer. 2017 Aug 15;16(1):137
pubmed: 28810877
Ann Coloproctol. 2022 Jun;38(3):253-261
pubmed: 35249276
Radiother Oncol. 2014 Oct;113(1):1-9
pubmed: 25281582
Ann Surg. 2004 Oct;240(4):711-7; discussion 717-8
pubmed: 15383798
Lancet Oncol. 2010 Sep;11(9):835-44
pubmed: 20692872
J Gastrointest Cancer. 2022 Aug 1;:
pubmed: 35915202
BMC Surg. 2014 Nov 18;14:94
pubmed: 25406793
Radiat Oncol. 2018 May 2;13(1):83
pubmed: 29720197
Med Sci Monit. 2017 Jan 19;23:315-324
pubmed: 28100902
J Cancer. 2018 Sep 7;9(18):3295-3302
pubmed: 30271489
Tumori. 2019 Oct;105(5):434-440
pubmed: 30117371
Cancer Manag Res. 2018 Dec 24;11:191-199
pubmed: 30636893
Anticancer Res. 2017 Mar;37(3):1459-1465
pubmed: 28314318
Radiother Oncol. 2022 Dec;177:9-15
pubmed: 36273737
World J Gastrointest Surg. 2020 Sep 27;12(9):390-396
pubmed: 33024513
Lancet. 2001 Feb 17;357(9255):539-45
pubmed: 11229684
Ann Coloproctol. 2022 Apr;38(2):97-108
pubmed: 35345306
Colorectal Dis. 2012 Oct;14(10):e701-7
pubmed: 22731833
Int J Radiat Oncol Biol Phys. 2021 Nov 1;111(3):816-825
pubmed: 34146635
In Vivo. 2020 Jul-Aug;34(4):2119-2126
pubmed: 32606192
Front Oncol. 2021 Mar 17;11:639909
pubmed: 33816284
N Engl J Med. 2022 Jun 23;386(25):2363-2376
pubmed: 35660797
Ann Oncol. 2017 Jul 1;28(suppl_4):iv22-iv40
pubmed: 28881920
J Surg Res. 2022 Jan;269:249-259
pubmed: 34624724
Int J Clin Oncol. 2020 Jul;25(7):1299-1307
pubmed: 32274615